कंपनी का अवलोकन
Foghorn Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity focused on the discovery and development of therapeutic medicines that target genetically determined dependencies within the chromatin regulatory system in the United States. The company leverages its proprietary Gene Traffic Control platform to identify and address specific biological mechanisms, positioning itself within the competitive healthcare landscape. This organization functions specifically within the Healthcare sector and the Biotechnology industry, a classification that signifies its engagement in high-risk, high-reward research and development phases prior to commercial product launch. The company's current market capitalization stands at $281.17M, supported by a total annual revenue of $30.91M and an operational workforce of 106 employees. These valuation and revenue figures indicate that the company is a mid-sized entity in the biotech space, possessing significant cash reserves relative to its revenue base but operating without the profitability metrics typical of mature pharmaceutical firms. The scale of operations reflects a capital-intensive model where the primary financial objective is advancing clinical trials rather than generating immediate operating income.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $30.91M, yet it posted a net income of $-74,283,000 and an EBITDA of $-78,775,000, revealing a substantial gap between top-line growth and bottom-line profitability. This wide disparity highlights an aggressive cost structure where research, development, and operational expenditures significantly exceed the revenue generated in the current fiscal period. Free cash flow stands at $-35,229,876, indicating that the company is currently burning cash to fund its proprietary platform and clinical activities, which limits immediate financial flexibility but is standard for clinical-stage development firms. The gross margin is reported at -176.5%, while the operating margin is -211.9% and the profit margin is -240.3%; these deeply negative figures reflect the heavy upfront costs of drug discovery and the lack of revenue contribution from products in late-stage development or commercialization. In terms of solvency, total cash holdings of $158.89M substantially exceed total debt of $41.27M, though the debt-to-equity ratio is listed as N/A due to the nature of the equity structure. The current ratio is 2.73, which indicates that the company holds 2.73 times more current assets than current liabilities, suggesting a robust position regarding short-term liquidity obligations. Return on Equity is N/A, whereas Return on Assets is -21.3%, a metric that reveals that management is utilizing the asset base to generate losses rather than returns at this stage of the business lifecycle.
मूल्यांकन आकलन
The P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -5.26, implying that the market is pricing in future profitability that has not yet been realized in the current financial statements. The Price to Book ratio is -2.50, which indicates a negative book value per share and suggests that the market cap does not cover the tangible net assets of the company in a traditional sense. The Price to Sales ratio is 9.10, and the EV/EBITDA is -2.08; these alternative valuation metrics suggest that the company is being valued based on revenue multiples and enterprise value adjustments rather than earnings power, which is common for pre-revenue or loss-making biotechs. The 52-week high is $6.95 and the 52-week low is $3.00, meaning the stock has experienced significant volatility within this trading range. Assuming the current market price aligns with the mid-range of recent activity, the stock is trading at a level that reflects the uncertainty surrounding clinical trial outcomes and regulatory approvals. The Beta value is 3.11, which signifies that the stock price is expected to fluctuate with 3.11 times the volatility of the broader market, exposing investors to heightened risk during periods of market instability.
Growth & Income
Revenue Growth (YoY) is reported at 223.8%, while Earnings Growth (YoY) is N/A due to the company's continued net losses. This dynamic implies that the top line is expanding rapidly, likely driven by new contracts, licensing deals, or revenue recognition from collaborations, whereas earnings are still negative as the company invests heavily in growth initiatives. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning all available cash is retained and reinvested into the Gene Traffic Control platform and clinical operations rather than distributed to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion offset by significant cash burn, with no current income generation from dividends or retained earnings distributions. This financial pattern is typical for clinical-stage biotechnology companies that prioritize capital allocation toward R&D milestones over immediate shareholder returns.